Latest News and Press Releases

- President and CEO Sean McCarthy, D. Phil., Appointed to Additional Role of Chairman -   - Hoyoung Huh, M.D., Ph.D. Retiring from Board - - James R. Meyers, Former EVP at Gilead Sciences,...

 - Demonstrates Further Proof-of-Mechanism of Probody™ Platform – - Consistent with CX-072 Clinical Observations at 2018 ASCO and ESMO Presentations- - Company to Host Analyst and Investor Event...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

ESMO Presentations Support CX-072 Product Profile and Probody™ Proof-of-Concept  Advancement of Clinical Stage Probody Drug Conjugate Programs, CX-2009 and CX-2029  CX-188 IND...

PROCLAIM-CX-072 Clinical Translational Data Presented as Poster and Rapid-Fire Oral Presentation Company to Host Analyst and Investor Event and Webcast SOUTH SAN FRANCISCO, Calif., Nov. ...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

- Additional Data Supports PD-L1 Targeting Probody CX-072 as Well Tolerated with Antitumor Activity as Monotherapy and in Combination with Ipilimumab - - Company to Host Conference Call and Webcast...

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...

- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) - ...